The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
full of good news saus
Did you see this Ray?
ow.ly/MNCu50Nmkzm #weareHInM
Professor Jane Eddleston, Group Medical Director for Manchester University NHS Foundation Trust, said: “Delivering earlier and more accurate detection, diagnosis, and prognosis, through collaboration, is key to tackling the health inequalities across Greater Manchester. Through our clinical research excellence and joint working with our city-region health innovation accelerator colleagues and strategic global corporate partners we will be able to identify the most prevalent issues affecting our communities and develop targeted patient-centred care and treatment.”
Professor Graham Lord, Vice-President and Dean of the Faculty of Biology, Medicine and Health at the University of Manchester, said: “We are delighted that our city region has been recognised as a powerhouse for healthcare and life sciences innovation and proud of The University of Manchester’s part in this success. The innovation accelerator programme has great potential to transform healthcare for the better in our region and more generally.”
In addition, a programme to develop a pipeline of new genomic technologies will be established, in collaboration with the University of Manchester. The Development and Validation of Technology for Time Critical Genomic Testing (DEVOTE) Programme will bring together academic, industry and clinical partners from across the region to deliver enhanced genomic diagnostics to prevent stroke; rapid genetic point of care devices to detect genetic changes; and the development of ‘pharmacogenetic passport’ to optimise precision medicines for patients.
Bill Newman, Professor of Translational Genomic Medicine at UoM, Consultant in Genomic Medicine at MFT, and a researcher with the National Institute for Health and Care Research (NIHR) Manchester BRC, said: “This is a great opportunity to enhance GM’s status as a world leader in creating genetic tests that can give rapid results in minutes. We expect that the DEVOTE projects will lead to the adoption of new tests by the NHS to make drug prescription safer and more effective. This will be good for patients and good for GM by creating jobs and a centre for investment in this cutting-edge science.”
Add to that that some of the above has commented on Gdr tweets over the last few months so unless I am Putting 2 and 2 and coming up with 5 there’s a good chance that it’s us. At least that’s my personal view .
They could have done that twice already and haven’t .
The company could use a platform like primary bid if it was say 50 and offer at a 20% discount to general public and existing holders .
Chances are if they have a bit of news like we are getting grant funding and the NHS have placed an order I reckon they would get the cash they may or may not need.EASILY.
I personally think the company has not raised because they know what’s coming.
Well paddy if that happens you will be talking about a raise at a higher level than now .
So if the stock was 50 you would expect a discount of say 20% which equates to a higher price than today’s close .
They could have raised easily over the last few months and chose not to ,ask yourself why not!
We have a few new ones talking about placing etc ,at least it’s not the same ones who said it at 8,10,12 before it went to 48p.
Grant funding according to the weekends press could be forthcoming .
We know Nice approval is likely next week and we have distributors in place across the world to sell our life changing kit into their respective healthcare situations.
Likely our own NHS will roll this out as the cost savings to them is significant .
All in all it’s healthy retrace but the danger for those trading it is that maybe the next spike won’t have a pullback .
? The big seller is out
BigAl some fair points made there
So grant funding could be waiting in the wings and/or someone from big pharma or similar wants to take a decent position either will do away with the need for a placing imoh.
Mr Budd could be playing a blinder here and catch a few out
Maybe just maybe before any award of grant funding is made they would need to have NICE approval in full.
And maybe Mr Budd has already been told what to expect and maybe he knows he might not need to raise any cash after ALL?
Just my personal view
ow.ly/MNCu50Nmkzm #weareHInM
Professor Jane Eddleston, Group Medical Director for Manchester University NHS Foundation Trust, said: “Delivering earlier and more accurate detection, diagnosis, and prognosis, through collaboration, is key to tackling the health inequalities across Greater Manchester. Through our clinical research excellence and joint working with our city-region health innovation accelerator colleagues and strategic global corporate partners we will be able to identify the most prevalent issues affecting our communities and develop targeted patient-centred care and treatment.”
Professor Graham Lord, Vice-President and Dean of the Faculty of Biology, Medicine and Health at the University of Manchester, said: “We are delighted that our city region has been recognised as a powerhouse for healthcare and life sciences innovation and proud of The University of Manchester’s part in this success. The innovation accelerator programme has great potential to transform healthcare for the better in our region and more generally.”
In addition, a programme to develop a pipeline of new genomic technologies will be established, in collaboration with the University of Manchester. The Development and Validation of Technology for Time Critical Genomic Testing (DEVOTE) Programme will bring together academic, industry and clinical partners from across the region to deliver enhanced genomic diagnostics to prevent stroke; rapid genetic point of care devices to detect genetic changes; and the development of ‘pharmacogenetic passport’ to optimise precision medicines for patients.
Bill Newman, Professor of Translational Genomic Medicine at UoM, Consultant in Genomic Medicine at MFT, and a researcher with the National Institute for Health and Care Research (NIHR) Manchester BRC, said: “This is a great opportunity to enhance GM’s status as a world leader in creating genetic tests that can give rapid results in minutes. We expect that the DEVOTE projects will lead to the adoption of new tests by the NHS to make drug prescription safer and more effective. This will be good for patients and good for GM by creating jobs and a centre for investment in this cutting-edge science.”
Read the runs again Budd says it starts in Manchester while we talk to the trusts Nationally .
So whoever is running the trusts at say London do you think that if you have a life changing kit that will save babies hearing and associated costs will not want to implement the same kit ASAP ?
Try explaining that one to the child’s parents when they know that they could have avoided that if they had the same kit as Manchester.
I don’t think the rollout will take very long on a wider scale
How is it poor news ? They have to start a roll out somewhere !
Given what tkevin found out over the weekend you would think that even more chance that some of that grant funding will come GDRs way
Not sure if anyone has said this but given the stream of buying over the last few weeks , could it be someone building a stake ahead of announcing a injection of cash into the company for say a 20% stake or more in the company at say 50p or more ?
Seen it before with big pharma buying a big position at a premium so why not here ?
That way no placing needed and big pharma to back the company ,any thoughts?
Not sure why they would given they wanted to fund it over a penny
Good spot tkevin
There doesn't have to be a TR1 as Helium was below 3% but they have def sold out
NU The main thing is Helium is out
The amount bought is sub 3% so dont expect to see who the buyer is .
The main thing is that Helium on the last holding in company was 189125000 shares , that amount was printed so THEY ARE OUT IMOH
genedrive plc
@genedriveplc
·
6m
A ‘world first’ in pre-emptive PGx testing. Not all scenarios lend themselves to a lab-based panel test due to time constraints - the Genedrive® MT-RNR1 ID Kit fits into the 1 hour prescribing window in line with NICE recommendations #GDR #genedrive
genomicseducation.hee.nhs.uk
A ‘world first’ in pre-emptive pharmacogenomic testing - Genomics Education Programme
The 7,000 patient PREPARE study showed a 30% reduction in adverse reactions to common clinically prescribed drugs after
genedrive plc
@genedriveplc
·
6m
Rapid testing in the
@PALOH_Study
using the Genedrive® MT-RNR1 ID Kit prevented antibiotic-induced hearing loss. The NICE EVA will highlight the powerful impact the test has on antibiotic use, without delaying urgent treatment for suspected #sepsis.
#GDR #hearingloss #POCT